LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

Strona główna・Stock List・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Closed

SectorHealthcare

99.64 -2.2

Buy Sell

Overview

Share price change

24h

Current

Min

98.88

Max

102.56

Key metrics
By Trading Economics
Income	2.9M -47M
Sales	16M 49M
Profit margin	-96.144
Employees	283
EBITDA	6.9M -40M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+9.75% upside

Dividends
By Dow Jones
Next Earnings	4 lis 2025

Market Stats
By TradingEconomics
Market Cap	896M 6.9B
Previous open	101.84
Previous close	99.64

News Sentiment

By Acuity

100%

84 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

60 / 65.58 Support & Resistance

Rhythm Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 wrz 2025, 23:59 UTC

Acquisitions, Mergers, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 wrz 2025, 22:02 UTC

Major Market Movers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 wrz 2025, 17:01 UTC

Major Market Movers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 wrz 2025, 17:01 UTC

Major Market Movers

Tron Shares Rise After New Investment From Bravemorning

8 wrz 2025, 16:14 UTC

Major Market Movers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 wrz 2025, 16:13 UTC

Major Market Movers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 wrz 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 wrz 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 wrz 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 wrz 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 wrz 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 wrz 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 wrz 2025, 21:47 UTC

Major Market Movers

Microsoft Signs $17.4B AI Deal With Nebius

8 wrz 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 wrz 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 wrz 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 wrz 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 wrz 2025, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 wrz 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 wrz 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 wrz 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 wrz 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 wrz 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 wrz 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 wrz 2025, 16:59 UTC

Market Talk

Acquisitions, Mergers, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 wrz 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 wrz 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 wrz 2025, 16:16 UTC

Earnings

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 wrz 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 wrz 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Rhythm Pharmaceuticals Inc Forecast

Price Target

By TipRanks

9.75% upside

12 Months Forecast

Average 112.08 USD 9.75%

High 135 USD

Low 95 USD

Based on 13 Wall Street analysts offering 12 month price targets forRhythm Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Rhythm Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

60 / 65.58Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

84 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.